Tue, Jul 22, 2014, 6:46 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Sarepta Therapeutics, Inc. Message Board

  • theman111knows theman111knows Dec 7, 2012 12:12 PM Flag

    "The Robustness of The Treatment Was Confirmed With the 62 Walking Test" link

    Street insider 12/7/12
    Sarepta Therapeutics Announces a Continued Benefit on Walking Test Through 62 Weeks in Phase IIb Open-Label Extension Study of Eteplirsen in Duchenne Muscular Dystrophy
    The 6MWT data were also evaluated through week 62 using the various methods of using the repeated test results including assessments of minimum values, average values, and the day 1 (first measure) values in assessing changes in 6MWT distance from baseline. Given the inherent variability in an effort-dependent outcome, such as a single-measure 6MWT, the robustness of the treatment effect seen with the prospectively specified analysis was confirmed with these additional analyses.

 
SRPT
21.88+0.31(+1.44%)Jul 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.